[ RadSafe ] Ra-223 Chloride - FDA Approval

[Brennan, Mike (DOH)]

"The U.S. Food and Drug Administration today approved Xofigo (radium Ra
223 dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone."

Note to self: don't get "castration-resistant prostate cancer".

How do you get Ra 223?  No path leaps out when I look at the chart of
the nuclides. 

-----Original Message-----
From: radsafe-bounces at health.phys.iit.edu
[mailto:radsafe-bounces at health.phys.iit.edu] On Behalf Of Chris Alston
Sent: Wednesday, May 15, 2013 2:03 PM
To: The International Radiation Protection (Health Physics) Mailing List
Subject: [ RadSafe ] Ra-223 Chloride - FDA Approval

Radsafers

Please see:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352363.htm

It is hard to tell from the notice.  But I thought that this drug (did
they change the name from Alpharadin, or is that a competitor still in
IND?) was  in trials for the relief of pain from metastases to bone, and
that, incidentally, the investigators showed that pts had extensions of
life (I hope, sincerely, of decent quality, relatively speaking).  Is it
approved for the latter use, or is the FDA just saying that was why they
fast-tracked it?

Cheers
cja
_______________________________________________
You are currently subscribed to the RadSafe mailing list

Before posting a message to RadSafe be sure to have read and understood
the RadSafe rules. These can be found at:
http://health.phys.iit.edu/radsaferules.html

For information on how to subscribe or unsubscribe and other settings
visit: http://health.phys.iit.edu